Ralph Riley, MBA is Global Director Precision Medicine Access and Policy Strategy at Johnson & Johnson. In his more than twenty-years at J&J he has worked across multiple disease areas to develop and commercialize testing to enable patient identification strategies and worked to shape policy to enable improved access policy for testing. Ralph has co-authored research articulating the value of diagnostics and precision medicine, the utility of next generation sequencing in lung cancer and lead research in epidemiology and modeling the use of biomarkers for chronic disease. He has spoken at many personalized medicine and access focused conferences regarding opportunities for evidence generation and access strategy related to testing and currently serves as a board member for From Testing to Targeted Treatment (FT3)- a multi-stakeholder organization seeking to improve access to testing for targeted therapies globally.